Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
NASONEX is a metered nasal spray containing mometasone furoate, a corticosteroid approved for nasal allergic conditions. It delivers anti-inflammatory therapy directly to nasal tissues via intranasal administration. The drug reduces nasal inflammation and allergy symptoms through local glucocorticoid receptor agonism.
Brand faces moderate competitive pressure (30/100) and approaching loss of exclusivity; team size likely stable but focused on transition strategy.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures
Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)
Working on NASONEX offers limited career expansion in a declining product lifecycle facing imminent generic competition. Roles emphasize defensive market tactics, managed care negotiations, and transition planning rather than growth innovation.
Worked on NASONEX at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.